Canaquest Medical Corporation · OTC:CANQF
Canaquest Medical — Investor Presentation (August 2019)
6 slides from Canaquest Medical's investor presentation, August 2019
Slide 1: Multi-Indication Blockbuster Potential
Multi-Indication Blockbuster Potential | Right Science. Right Team. Right Timing. Five targeted indications • Epilepsy, Depression, PTSD, anxiety, TBI Designated pathway to orphan drug status for epilepsy Well-defined IP strategy and platform formulation Scalable platform across CNS disorder
Slide 2: Product Differentiation
Product Differentiation | CQ-001: A best-in-class treatment for epilepsy Drug Mechanism of Action Tolerability Efficacy Cognition Attach to CB1 & CB2 Epidiolex receptors Moderate Effective Limited (Jazz Pharma) (Cannabidiol only) PPAR activation CQ-001 (CanaQuest) (Cannabidiol + propriatory High ↑ 3
Slide 3: Market Opportunity
Market Opportunity | Global Market for Refractory Epilepsy Globally: 17.5M refractory epilepsy patients US & Canada: ~70,000 patients • $2.8B+ serviceable addressable market Safer alternative to Epidiolex Cannabinoid platform for new indications Best-in-class advantage in rare syndromes
Slide 4: Market Opportunity
Market Opportunity | A $1.9B+ Global Market in Epilepsy Alone High-Impact Entry into a $1.9 B+ Epilepsy Market Alone 🔹 50 million patients globally suffer from epilepsy 🔹 30% - 40% (~17.5M) have refractory epilepsy – underserved & drug-resistant 🔹 $1.9B global market, expanding with high unmet…
Slide 5: Summary: Seven Reasons to Invest in CanaQuest
SUMMARY | Seven Reasons to Invest in CanaQuest
Slide 6: Why Now?
Why Now? | Right Team. Right Science. Right Timing. 🔹 Regulatory momentum: FDA precedent set by Epidiolex opens the path 🔹 Orphan Drug Designation in progress → 7-year exclusivity potential 🔹 Mental health and epilepsy are urgent global priorities 🔹 Backed by $11M+ soft circled, incl. former GW…
CanaQuest Medical — Investor Presentation (August 2019) on 6ix